Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) VP Ken Moseley sold 2,200 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $20.01, for a total transaction of $44,022.00. Following the completion of the sale, the vice president now owns 1,044 shares of the company’s stock, valued at approximately $20,890.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ken Moseley also recently made the following trade(s):

  • On Monday, August 15th, Ken Moseley sold 1,000 shares of Bellicum Pharmacueticals stock. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00.

Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) opened at 19.71 on Wednesday. The firm’s market cap is $533.12 million. The stock’s 50 day moving average is $18.26 and its 200 day moving average is $13.14. Bellicum Pharmacueticals Inc. has a 52 week low of $7.24 and a 52 week high of $23.84.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/bellicum-pharmacueticals-inc-blcm-vp-sells-44022-00-in-stock.html

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.04. Bellicum Pharmacueticals had a negative return on equity of 42.22% and a negative net margin of 21,774.65%. During the same quarter last year, the firm posted ($0.40) EPS. Equities research analysts expect that Bellicum Pharmacueticals Inc. will post ($2.34) EPS for the current year.

A number of equities research analysts have issued reports on BLCM shares. Jefferies Group reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 23rd. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, August 29th. SunTrust Banks Inc. started coverage on shares of Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 target price for the company. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $31.00 target price (up previously from $25.00) on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 9th. Finally, Citigroup Inc. upgraded shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $24.25.

Several large investors have recently modified their holdings of BLCM. ProShare Advisors LLC boosted its position in shares of Bellicum Pharmacueticals by 10.6% in the second quarter. ProShare Advisors LLC now owns 22,654 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 2,163 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Bellicum Pharmacueticals by 4.0% in the first quarter. Geode Capital Management LLC now owns 64,665 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 2,513 shares in the last quarter. BlackRock Group LTD boosted its position in shares of Bellicum Pharmacueticals by 27.9% in the first quarter. BlackRock Group LTD now owns 12,443 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 2,713 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Bellicum Pharmacueticals by 24.4% in the second quarter. Alliancebernstein L.P. now owns 19,400 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 3,800 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bellicum Pharmacueticals by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,509 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 3,888 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Bellicum Pharmacueticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

5 Day Chart for NASDAQ:BLCM

Receive News & Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.